Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Broyhill Asset Management Christopher R. Pavese | “Sotera Health ($SHC) provides mission-critical sterilization, lab testing, and advisory services essential for medical devices and pharmaceuticals. Broyhill initiated the position after headline litigation risks related to ethylene oxide emissions caused market participants to overlook the company's defensive duopoly characteristics. Because Sotera is one of only two scaled providers capable of sterilizing critical medical equipment, Broyhill views the business as an essential component of healthcare infrastructure with irreplaceable terminal value. From an economic standpoint, the company possesses an exceptionally wide regulatory and operational moat with virtually no viable commercial substitutes for its sterilization processes. The market's exaggerated focus on litigation created an opportunity to purchase the business at an attractive valuation multiple of roughly 14x forward earnings, representing a steep discount to its primary peer trading near 20x. High switching costs and long-term regulatory compliance requirements generate stable pricing power and strong operating leverage as sterilization volumes rebound. Key forward catalysts include volume normalization following management's strongest shipment months in years and regulatory relief via the EPA's proposed repeal of stringent 2024 ethylene oxide rules. Primary downside risks revolve around adverse courtroom developments in pending tort litigation and localized operational interruptions at facility sites.” | BULL | Q2 2026 Sep 1, 2026 | View Pitch |
McIntyre Partnerships Chris McIntyre | “SHC saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024. Further, SHC also had positive” | NEUTRAL | Q2 2026 Aug 6, 2026 | View Pitch |
McIntyre Partnerships Chris McIntyre | “SHC saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024. Further, S...” | BULL | Q2 2026 Aug 6, 2026 | View Pitch |
O'Keefe Stevens Advisory, Inc Dominick D'Angelo | “We have been following Sotera Health for several years. The business is exceptional: a sterilization duopoly with Sterigenics and Steris combined controlling an estimated 70% of the sterilization market. Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. Yet we never bought it because of one thing: Warburg Pincus held a material stake and was consistently selling into the market. We do not buy high-quality businesses where forced sellers will pressure the stock regardless of fundamental improvement. We look for situations where forced sellers create dislocation, allowing us to buy a stock for cheaper than what it would trade for without such selling pressure. On the flip side, we look to sell into forced buyers pushing stock prices up irrespective of fundamentals. In early 2026, Warburg sold its last share. Combined with a valuation that was cheap given the quality of the business model, we thought it made sense to purchase the stock. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Sterigenics represents over 60% of revenue, and we expect it to grow at mid to high single digits organically. The company targets cumulative free cash flow of $500m-$600m over the three-year period, which we expect will be much higher post-2027 when capex runs at a more normalized level. Sotera recently completed capacity expansions and greenfield buildouts, which elevated capex. As those projects mature, capacity is absorbed, and CapEx will normalize and decline, driving higher cash conversion. Cash flow will go toward debt reduction, with net leverage currently at 3.2x. Outstanding ethylene oxide litigation, concentrated in California and Georgia, is expected to be resolved by the end of 2027. When litigation risk abates and the balance sheet improves, the market will price the business on its fundamental quality: a duopoly sterilization franchise with 50% EBITDA margins, 20 consecutive years of revenue growth, and management executing a credible margin improvement plan. Today, the stock is depressed by litigation headlines and a balance sheet that is more levered than we would like, in conjunction with the potential legal payout. In May 2026, Alton Shader took over as CEO. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Prior CEO Petras, who scaled the company from $600m in 2016 revenue to $1.6B in 2025, remains as executive chairman focused on investor relations, commercial operations, and litigation strategy. We believe this is a step in the right direction. Petras had to balance operational management with significant litigation oversight. Shader can dedicate substantially all of his time to operating the business efficiently. Our experience is that when management has ongoing time spent outside the core business, even a high-quality business is not immune to bloat and less-than-perfect operational practices. When these distractions end, operational improvements typically follow. Sotera's 20 years of consecutive revenue growth and 50% EBITDA margins suggest a very high-quality business. Steris has not gone through similar litigation, and thus has taken share during this. We expect a focused management team to regain share. The business model's durability stems from three interlocking dynamics. First, switching costs are extraordinarily high. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. A device sterilized in one location cannot simply move to another without undergoing significant re-qualification. That regulatory friction creates a durable moat. Customers are effectively locked in. Second, the sterilization service represents a low single-digit percentage of the total manufacturing cost of a medical device. Because it is such a small percentage of overall device cost, customers are willing to pay for convenience and reliability rather than shop aggressively on price. Geography matters enormously. Shipping a device from Michigan to Arizona (for example) for sterilization becomes economically irrational when a facility exists nearby. Sotera's geographic footprint means customers pay a premium for proximity and certainty, not to compete on commodity pricing. Third, regulation has created supply-side dynamics that favor consolidated operators. In April 2024, the EPA finalized stricter ethylene oxide emissions standards for sterilization facilities. Sterigenics responded by committing roughly $200m of capital to upgrade its facilities to comply with the strictest version of the rule. In 2026, this capex should total ~$50m and will largely complete facility improvements. In July 2025, the Trump administration granted two-year compliance extensions to 41 sterilization facilities, acknowledging that the 2024 rule would force closures. Even with those extensions, smaller operators are under pressure. KPR's Augusta, Georgia facility is closing, affecting over two hundred employees. Cosmed Group filed for bankruptcy under EtO litigation exposure. As supply comes offline and capacity remains constrained, Sotera will capture displaced volume at improved pricing. In March 2026, the Trump administration proposed rescinding and relaxing key portions of the 2024 rule, citing concerns about facility closures and domestic medical device supply chain disruption. The public comment period closed May 15, 2026, and the EPA should finalize a decision within the next year. Regardless of which direction the final rule takes, Sotera stands to benefit. Industry-wide sterilization capacity is running tight. Sotera targets 80% utilization across its portfolio, and management reports a good operational position globally despite occasional regional pinch points. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. If the agency relaxes the standards, the majority of Sotera's compliance capex is already behind them and should lower the probability of future litigation risk. We see 50% near-term upside; however, we are planning to own this durable business for many years. Post-litigation, we would label this as a compounder.” | BULL | Q2 2026 Jul 25, 2026 | View Pitch |
McIntyre Partnerships Chris McIntyre | “SHC's stock was volatile in 2025 but ultimately finished strong. Despite the share price volatility, SHC remains a predictable, growing, and recession-proof business. These are exactly the attributes we look for in a core holding. Despite the noise, the core business remains a stable franchise that has consistently grown sales and operating profits with zero down years in the last 20 years. Further, 2025 marked an inflection year, with the core Sterigenics segment posting 10% revenue growth, up from ~4-7% in the previous two years. This inflection was driven by Sterigenics finally lapping the inventory destocking that hospitals and distributors saw following COVID-19 hoarding, which lifted volumes from flat to ~5% growth. With destocking in the rearview mirror, SHC is well positioned to return to its historical 10%+ EBITDA growth rate, which is above Street estimates and, I believe, represents a significant catalyst. In addition, SHC should benefit from the tax law changes in the OBBB Act. SHC has been paying a ~34% tax rate because the 2017 tax law lowered the interest deductibility cap from 30% of EBITDA to 30% of EBIT in 2022. The new tax law restores deductibility to EBITDA, which, combined with SHC's growth and debt paydown, will reduce SHC's tax rate to the mid-twenties. However, despite the change in the law, the Street still models SHC's tax rate around 32%. When SHC reports, I anticipate guidance confirming the lowered tax rate, which should boost EPS estimates by ~10%. SHC also saw solid developments on the legal front. They continued to make progress and settled numerous cases in line with previous settlements. Further, SHC saw a significant number of cases dismissed in Georgia for failure to prove causation, which should reduce the future value of settlements in the state. While I anticipate SHC will continue to face litigation and pay settlements, I believe the largest settlements are behind them, and further settlements, like the $31MM in April 2025, are minor bumps rather than material headwinds. Despite improved volumes, changes in tax law, and positive legal developments, SHC remains at a material discount to STE, the other side of their sterilization duopoly. For comparison, STE trades ~25x 2026 EPS and 21x 2027 EPS, versus SHC at 17x and 14x my estimates, respectively. Given the inflecting growth and discount to peers, we retain a large position. I believe our investment is positioned to benefit from SHC's ~10% EBITDA growth per year, continuing capital returns, and potential multiple expansion. I value SHC at 25x my 2027 EPS estimate of $1.20, implying a $30 valuation versus its current $17 price. BSD Analysis: Sotera Health enters 2026 as a leading global provider of mission-critical sterilization and lab testing services, currently recovering from a period of significant litigation-related volatility. The company is focusing on a "back to basics" strategy, emphasizing the essential nature of its end-to-end healthcare solutions for the medical device and pharmaceutical industries. Management has prioritized deleveraging the balance sheet and improving operational efficiency, with recent earnings prints showing a steady return to mid-single-digit organic growth. While regulatory scrutiny on ethylene oxide remains a persistent narrative, Sotera's diverse technology portfolio and dominant market share provide a strong defensive buffer. Analysts are increasingly optimistic about the company's ability to drive margin expansion through specialized lab advisory services, making it a compelling recovery play in the healthcare supply chain.” | BULL | Q4 2025 Feb 19, 2026 | View Pitch |
McIntyre Partnerships Chris McIntyre | “Over the last two years, SHC has been experiencing an atypical downturn in its end markets. I describe it as atypical, as one does not normally think of things like hip replacements and syringes as economically sensitive. However, excessive stocking of medical equipment during COVID and hoarding during the 2021 supply chain shortages created bloated inventories at hospitals and distributors, which, as these customers returned to normal inventory levels, resulted in flat volumes versus SHC's historical mid-single digit volume growth. While SHC's share price has expressed great skepticism, given my belief in SHC's dominant position and long-term healthcare trends, I was confident it was a matter of when, not if, SHC's volumes recovered. During H1, management's tone began to change regarding the recovery, and SHC reported 6% volume growth in Q2, confirming my thesis and driving SHC's shares from -16% YTD at the end of June to +21% at the end of August. For perspective, SHC grew volumes 4-7% from 2019 through 2022, and during that time SHC traded 18-22x EBITDA. If SHC can return to its historical EBITDA growth of ~10%, I believe SHC will again be viewed as a consistent compounder, warranting a high multiple. 18x my 2027 EBITDA estimate would yield $35 versus the current $16 price. BSD Analysis: SHC is emerging from a multi-year destocking cycle that masked its stable, non-cyclical end-market demand. The return to mid-single-digit volume growth validates the company's competitive moat and suggests EBITDA normalization ahead. Shares trade at a steep discount to historical sterilization comps despite improving fundamentals and reduced legal overhang. With operating leverage, SHC could compound EBITDA at ~10% annually, justifying a re-rating toward high-teens EV/EBITDA multiples. A return to normalized procedure volumes, incremental capacity additions, and potential pricing tailwinds are key catalysts.” | BULL | Q2 2025 Sep 3, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
